Advanced Search:
Equity Index

BAI.AS - BENEVOLENTAI

€0.55  -0.008 (-1.43%)

Updated: 08:02 May 10, 2024 EST

Next Session's AI Forecast

97.6%

Avg. Accuracy (AI)

€0.6

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€0.46

BENEVOLENTAI's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

BENEVOLENTAI - HISTORICAL DATA 6M

  • Last price

    €0.55

  • Daily change

    €-0.008

  • Previous Close

    €0.56

  • Last Updated

    08:02 May 10, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-3.23 -1.35 -0.45 -1.12 -1.26

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
3.23 3.98 3.7 4.81 4.47

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 0% 0% 0%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
0.57 -10.94% 0.64 -3.03% 0.66 -12% 0.75

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.5 20 1 33.33

BENEVOLENTAI Technical Analysis News

BENEVOLENTAI

4-8 Maple Street
London W1T 5HD
United Kingdom
44 20 3781 9360
https://www.benevolent.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 248
Description

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

Corporate Governance

BenevolentAI S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.